NAMUR, Belgium, Sept. 7, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer, today announced that its Chief Executive Officer, Cameron Reynolds, and its Vice President of Investor Relations, Scott Powell, are scheduled to attend and present at several conferences in September.
During their presentations, Mr. Reynolds and Mr. Powell will outline Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced European commercialization strategy for its Nu.Q blood-based tests for colorectal cancer.
Details of the conferences are as follows:
2016 Wells Fargo Healthcare Conference
Thursday, September 8, 2016
The Westin Boston Waterfront, Boston
Rodman & Renshaw 18th Annual Global Investment Conference
Monday, September 12, 2016
12:05 p.m. EDT
Lotte New York Palace Hotel, New York City
17th Annual GCFF Toronto Conference 2016
Saturday, September 17, 2016
10:45 a.m. EDT
Courtyard Toronto Northeast/Markham, Markham, ON
2016 Aegis Growth Conference
Wednesday, September 21, 2016
1:00 p.m. PDT
The Encore at Wynn, Las Vegas
MicroCap Leadership Summit
Friday, September 23, 2016
8:30 a.m.-4:00 p.m. CDT (Small Group Presentations)
Westin Chicago Northwest Hotel, Itasca, IL
Persons attending the conferences who would like to schedule a 1-on-1 meeting with Volition management during the conference may do so by contacting Tirth Patel of Edison Advisors at email@example.com or Scott Powell, Vice President of Investor Relations of Volition, at S.Powell@volitionrx.com.
Volition is a life sciences company focused on developing diagnostic tests for cancer. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.
Volition's goal is to make the tests as easy and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. Volition's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
Media / Investor Contacts
Louise Day, Volition
Scott Powell, Volition
+44 (0)7557 774 620
+1 (646) 650-1351
Tirth Patel, Edison Advisors
Katherine Fennell, Edison Advisors
+1 (646) 653-7035
+44 (0) 20 7841 1556
Nucleosomics®, NuQ® and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-to-attend-several-conferences-in-september-300322952.html
SOURCE VolitionRx Ltd